SMBC Nikko initiated coverage on Agenus with a new price target
$AGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
SMBC Nikko initiated coverage of Agenus with a rating of Outperform and set a new price target of $5.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/19/2024 | $35.00 → $8.00 | Outperform → Neutral | Robert W. Baird |
| 7/18/2024 | Outperform → Mkt Perform | William Blair | |
| 7/18/2024 | $9.00 | Buy → Neutral | H.C. Wainwright |
| 6/6/2023 | $8.00 | Outperform | Robert W. Baird |
| 6/6/2023 | $60.00 → $80.00 | Outperform | Robert W. Baird |
| 2/28/2023 | $8.00 | Buy | H.C. Wainwright |
| 9/28/2022 | $5.00 | Outperform | SMBC Nikko |
| 3/2/2022 | $12.00 → $14.00 | Buy | HC Wainwright & Co. |
SC 13G/A - AGENUS INC (0001098972) (Subject)
SC 13G/A - AGENUS INC (0001098972) (Subject)
SC 13G/A - AGENUS INC (0001098972) (Subject)
Jefferies analyst Biren Amin downgrades Agenus (NASDAQ:AGEN) from Buy to Hold and raises the price target from $3 to $7.
Thursday, Agenus Inc. (NASDAQ:AGEN) announced the results of its end-of-Phase 2 meeting with the FDA to advance its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for adult patients with relapsed/refractory microsatellite-stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM). The FDA discouraged the accelerated approval pathway and advised against submitting these results to support an Accelerated Approval based on its view that objective response rates may not translate to survival benefits. Given the limited treatment options for late-stage colorectal cancer and the promising survival data from the Phase I trial of botensilimab plus balsti
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Thursday. The Dow traded down 1.08% to 40,752.05 while the NASDAQ fell 0.80% to 17,853.34. The S&P 500 also fell, dropping, 0.75% to 5,546.48. Check This Out: Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July Leading and Lagging SectorsEnergy shares jumped by 1.1% on Thursday. In trading on Thursday, health care shares fell by 1.6%. Top Headline Abbott Laboratories (NYSE:ABT) reported better-than-expected earnings for its second quarter on Thursday. The company posted sales of $10.38 billion, up 4%, almost in line with the consensus of $10.37 bil
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline Agenus Inc. (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising. Tom Harrison's Background Highlights: Chairman Emeritus of Diversified Agency Services (DAS), Omnicom Group Inc.: Harrison led the world's largest group of marketing services companies, overseeing an unparalleled range of services including public relations, crisis management, bran
Strategic leadership to drive next phase of growth for the company Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensures a seamless integration of strategic insights across both organizations, enhancing our collaborative efforts to innovate and deliver breakthrough cancer therapies.
Robin Taylor, MBA, Ph.D., Appointed Chief Commercial Officer Homa Yeganegi Appointed Chief Product Strategy and Global Medical Affairs Officer Stephanie Fagan Appointed Chief Communications Officer Immuno-oncology leader, Agenus Inc. ("Agenus") (NASDAQ:AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The newly appointed leaders bring a wealth of industry experience to drive the company's next phase of growth in the development and planned commercialization of botensilimab and a deep pipeline of immuno-oncology programs, which offer potential breakthroughs in cancer therapeutics. Chief Commercial Officer, Robin Ta
10-Q - AGENUS INC (0001098972) (Filer)
8-K - AGENUS INC (0001098972) (Filer)
8-K/A - AGENUS INC (0001098972) (Filer)
Transforming Cancer Treatment with BOT/BAL While Strengthening Financial Foundations Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024. "BOT/BAL represents one of the most significant advancements in cancer immunotherapy, showing remarkable results in MSS colorectal cancer where previous treatments have fallen short," said Garo Armen, Ph.D., Chairman and CEO of Agenus. "Its potential extends beyond this challenging cancer type, with promising efficacy seen in the neoadjuvant setting and other hard-to-treat cancers. While we are excited by
Novel Candidates Show Promise in Turning Cold and Refractory Tumors into Responsive Targets Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the presentation of new data on two of its promising investigational immunotherapy candidates, botensilimab and AGEN1721, at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting in Houston, Texas. The data, showcasing potential breakthroughs in treating immune-resistant tumors, will be presented by Dhan Chand, Ph.D., Vice President of Research at Agenus. The first two presentations will spotlight botensilimab, an innovative, investigational, Fc-enhanced ant
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
Robert W. Baird downgraded Agenus from Outperform to Neutral and set a new price target of $8.00 from $35.00 previously
William Blair downgraded Agenus from Outperform to Mkt Perform
H.C. Wainwright downgraded Agenus from Buy to Neutral and set a new price target of $9.00
Transforming Cancer Treatment with BOT/BAL While Strengthening Financial Foundations Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024. "BOT/BAL represents one of the most significant advancements in cancer immunotherapy, showing remarkable results in MSS colorectal cancer where previous treatments have fallen short," said Garo Armen, Ph.D., Chairman and CEO of Agenus. "Its potential extends beyond this challenging cancer type, with promising efficacy seen in the neoadjuvant setting and other hard-to-treat cancers. While we are excited by
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2024 financial results before the market opens on Tuesday, November 12th, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/932317413. About A